Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports

BackgroundTrastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated substantial clinical activity in metastatic HER2-positive breast cancer. Although durable responses are increasingly reported, the potential for long-lasti...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Zelmira Ballatore, Helene Vanacker, Rita Chiari, Thomas Bachelot
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2025-10-01
Reeks:	Frontiers in Oncology
Onderwerpen:	breast cancer HER2 breast cancer + Trastuzumab deruxtecan (T-DXd) antibody drug conjugate (ADC) HER - 2/neu
Online toegang:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1647018/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!